Stock Concentration on Shares of Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC)

Individual investors are constantly striving to stay on top of the equity markets. Spotting opportunity may involve a lot of hard work and preparation. Investors are usually examining every piece of information available. This may entail keeping close watch on fundamental and technical data. Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) has a current Value Composite Score of 95. Using a scale from 0 to 100, a lower score would represent an undervalued company and a higher score would indicate an expensive or overvalued company.  This ranking was developed by James O’Shaughnessy using six different valuation ratios including price to book value, price to sales, EBITDA to EV, price to cash flow, price to earnings, and shareholder yield.

Interested investors may be looking at the Magic Formula (MF Rank) on shares of Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC). Currently, the company has an MF Rank of 16952. Successful hedge fund manager Joel Greenblatt developed the Magic Formula which was introduced in his book “The Little Book That Beats the Market”. Greenblatt was focused on a method for identifying bargains when purchasing company shares. This included spotting companies that earn more relative to the stock price, or companies with a high earnings yield. The Magic Formula may help spot good, healthy companies. The MF is calculated using earnings yield and ROIC ratios. In general, investors may be searching for stocks with the lowest combined MF Rank.

Shifting the focus to some ROIC (Return on Invested Capital) numbers, Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC)’s ROIC is -2.630161. The ROIC 5 year average is -1.95642 and the ROIC Quality ratio is -1.417505. ROIC is a profitability ratio that measures the return that an investment generates for those providing capital. ROIC helps show how efficient a company is at turning capital into profits. ROIC may be a good measure to view when examining whether or not a company is able to invest wisely. ROIC may also be an important metric for the value investor who is trying to determine the company’s moat.

Traders may also be following some financial ratios for Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC). Currently, the firm has a Gross Margin (Marx) ratio of -0.503046. This number is based off of the research by University of Rochester professor Robert Novy-Marx. Marx believed that a high gross income ratio was a sign of a quality company. Looking further, Cyclacel Pharmaceuticals, Inc. has a Gross Margin score of 44. This score is based on the Gross Margin (Marx) metric using a scale from 1 to 100 where a 1 would be seen as positive, and a 100 would be regarded as negative.

Investors may also be paying increased attention to the EV for Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC). The company currently has an EV or Enterprise Value of 11390. The EV helps show how the market assigns value to a company as a whole. EV is a modification of market cap, as it incorporates debt and cash for assessing a firm’s valuation. Watching a firm’s EV may be useful when comparing companies with different capital structures. EV can help investors gain a truer sense of whether a company is undervalued or not.

Leave a Comment